{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:11:53Z","timestamp":1778793113341,"version":"3.51.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,8,29]],"date-time":"2015-08-29T00:00:00Z","timestamp":1440806400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s10792-015-0124-0","type":"journal-article","created":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T15:40:08Z","timestamp":1440776408000},"page":"903-912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Biologic therapy for refractory scleritis: a new treatment perspective"],"prefix":"10.1007","volume":"35","author":[{"given":"Tania Sales de Alencar","family":"de Fidelix","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Antonio","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"de Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia Fernandes Mo\u00e7a","family":"Trevisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,29]]},"reference":[{"key":"124_CR1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.preteyeres.2013.02.004","volume":"35","author":"D Wakefield","year":"2013","unstructured":"Wakefield D, Di Girolamo N, Thurau S, Wildner G, McCluskey P (2013) Scleritis: immunopathogenesis and molecular basis for therapy. Prog Retin Eye Res 35:44\u201362. doi: 10.1016\/j.preteyeres.2013.02.004","journal-title":"Prog Retin Eye Res"},{"key":"124_CR2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jfo.2012.12.004","volume":"36","author":"CS Foster","year":"2013","unstructured":"Foster CS (2013) Ocular manifestations of the potentially lethal rheumatologic and vasculitic disorders. J Fr Ophtalmol 36:526\u2013532. doi: 10.1016\/j.jfo.2012.12.004","journal-title":"J Fr Ophtalmol"},{"key":"124_CR3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/bjo.60.3.163","volume":"60","author":"PG Watson","year":"1976","unstructured":"Watson PG, Hayreh SS (1976) Scleritis and episcleritis. Br J Ophthalmol 60:163\u2013191","journal-title":"Br J Ophthalmol"},{"key":"124_CR4","doi-asserted-by":"crossref","unstructured":"Kraus CL, Culican SM (2012) Use of biologic agents in ocular manifestations of rheumatic disease. Int J Rheumatol 203819","DOI":"10.1155\/2012\/203819"},{"key":"124_CR5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/09273940590951034","volume":"13","author":"AA Okada","year":"2005","unstructured":"Okada AA (2005) Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 13:335\u2013351","journal-title":"Ocul Immunol Inflamm"},{"key":"124_CR6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244\u2013279","journal-title":"Pharmacol Ther"},{"key":"124_CR7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/ICU.0b013e32833f1060","volume":"21","author":"A Rachitskaya","year":"2010","unstructured":"Rachitskaya A, Mandelcorn ED, Albini TA (2010) An update on the cause and treatment of scleritis. Curr Opin Ophthalmol 21:463\u2013467. doi: 10.1097\/ICU.0b013e32833f1060","journal-title":"Curr Opin Ophthalmol"},{"key":"124_CR8","first-page":"212","volume":"61","author":"R Herrera-Esparza","year":"2009","unstructured":"Herrera-Esparza R, Avalos-Diaz E (2009) Infliximab treatment in a case of rheumatoid scleromalacia perforans. Reumatismo 61:212\u2013215","journal-title":"Reumatismo"},{"key":"124_CR9","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3129\/i09-061","volume":"44","author":"HN Sen","year":"2009","unstructured":"Sen HN, Sangave A, Hammel K, Levy-Clarke G, Nussenblat RB (2009) Infliximab for the treatment of severe scleritis. Can J Ophthalmol 44:e9\u2013e12","journal-title":"Can J Ophthalmol"},{"key":"124_CR10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bjo.2008.150961","volume":"94","author":"P Doctor","year":"2010","unstructured":"Doctor P, Sultan A, Syed S, Christen W, Bhat P, Foster CS (2010) Infliximab for the treatment of refractory scleritis. Br J Ophthalmol 94:579\u2013583. doi: 10.1136\/bjo.2008.150961","journal-title":"Br J Ophthalmol"},{"key":"124_CR11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10384-010-0889-7","volume":"55","author":"JY Oh","year":"2011","unstructured":"Oh JY, Kim MK, Wee WR (2011) Infliximab for progressive peripheral keratitis in a patient with juvenile rheumatoid arthritis. Jpn J Ophthalmol 55:70\u201371. doi: 10.1007\/s10384-010-0889-7","journal-title":"Jpn J Ophthalmol"},{"key":"124_CR12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3109\/09273941003624914","volume":"18","author":"M Jabbarvand","year":"2010","unstructured":"Jabbarvand M, Fard MA (2010) Infliximab in a patient with refractory necrotizing scleritis associated with relapsing polychondritis. Ocul Immunol Inflamm 18:216\u2013217. doi: 10.3109\/09273941003624914","journal-title":"Ocul Immunol Inflamm"},{"key":"124_CR13","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/rheumatology\/keh635","volume":"44","author":"D Ashok","year":"2005","unstructured":"Ashok D, Ayliffe WH, Kiely PD (2005) Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy. Rheumatology (Oxford) 44:950\u2013951. doi: 10.1093\/rheumatology\/keh635","journal-title":"Rheumatology (Oxford)"},{"key":"124_CR14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.eye.6701457","volume":"19","author":"S Cazabon","year":"2005","unstructured":"Cazabon S, Over K, Butcher J (2005) The successful use of infliximab in resistant relapsing polychondritis and associated scleritis. Eye (Lond) 19:222\u2013224","journal-title":"Eye (Lond)"},{"key":"124_CR15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0161-6420(03)00721-8","volume":"111","author":"C Murphy","year":"2004","unstructured":"Murphy C, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D (2004) Tumor necrosis factor blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111:352\u2013356","journal-title":"Ophthalmology"},{"key":"124_CR16","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/sj.eye.6701712","volume":"19","author":"Y El-Shabrawi","year":"2005","unstructured":"El-Shabrawi Y, Hermann J (2005) Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener\u2019s granulomatosis. Eye (Lond) 19:1017\u20131018. doi: 10.1038\/sj.eye.6701712","journal-title":"Eye (Lond)"},{"key":"124_CR17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.rhu.0000249766.24780.95","volume":"12","author":"II Atchia","year":"2006","unstructured":"Atchia II, Kidd CE, Bell RW (2006) Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J Clin Rheumatol 12:291\u2013293. doi: 10.1097\/01.rhu.0000249766.24780.95","journal-title":"J Clin Rheumatol"},{"key":"124_CR18","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/archopht.125.7.895","volume":"125","author":"L Sobrin","year":"2007","unstructured":"Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS (2007) Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 125:895\u2013900. doi: 10.1001\/archopht.125.7.895","journal-title":"Arch Ophthalmol"},{"key":"124_CR19","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00417-007-0634-1","volume":"245","author":"K Weiss","year":"2007","unstructured":"Weiss K, Rieger R, Keitzer R, Pleyer U (2007) Successful infliximab treatment of posterior scleritis in a 13-year-old child refractory to other immunosuppressive. Graefes Arch Clin Exp Ophthalmol 245:1735\u20131737","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"124_CR20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s10384-008-0652-5","volume":"53","author":"SJ Ahn","year":"2009","unstructured":"Ahn SJ, Oh JY, Kim MK, Wee WR (2009) Treating refractory scleritis with infliximab. Jpn J Ophthalmol 53:286\u2013287. doi: 10.1007\/s10384-008-0652-5","journal-title":"Jpn J Ophthalmol"},{"key":"124_CR21","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1111\/j.1755-3768.2010.02090.x","volume":"90","author":"Y Sassa","year":"2012","unstructured":"Sassa Y, Kawano Y, Yamana T, Mashima T, Ishibashi T (2012) A change in treatment from etanercept to infliximab was effective to control scleritis in a patient with rheumatoid arthritis. Acta Ophthalmol 90:e161\u2013162. doi: 10.1111\/j.1755-3768.2010.02090.x","journal-title":"Acta Ophthalmol"},{"key":"124_CR22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/09273940802023786","volume":"16","author":"N Huynh","year":"2008","unstructured":"Huynh N, Cervantes-Castaneda RA, Bhat P, Gallagher MJ, Foster CS (2008) Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm 16:89\u201393. doi: 10.1080\/09273940802023786","journal-title":"Ocul Immunol Inflamm"},{"key":"124_CR23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.medcli.2009.02.010","volume":"134","author":"GMA Medina","year":"2010","unstructured":"Medina GMA, Dom\u00ednguez JG, Villaverde GR, Alvarez ER (2010) Infliximab para el tratamento de la escleritis anterior necrosante associada a artritis reumatoide seropositiva. Med Clin (Barc) 134:234\u2013236","journal-title":"Med Clin (Barc)"},{"key":"124_CR24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5","volume":"45","author":"JR Smith","year":"2001","unstructured":"Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, Rosenbaum JT (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 45:252\u2013257. doi: 10.1002\/1529-0131(200106)45:3<252:AID-ART257>3.0.CO;2-5","journal-title":"Arthritis Rheum"},{"key":"124_CR25","first-page":"405","volume":"79","author":"D D\u00edaz-Valle","year":"2009","unstructured":"D\u00edaz-Valle D, S\u00e1nchez RM, Espartero MCF, Allen DP (2009) Tratamiento de la escleritis anterior difusa refractaria con infliximab. Arch Soc Esp Oftalmol 79:405\u2013408","journal-title":"Arch Soc Esp Oftalmol"},{"key":"124_CR26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10067-009-1368-8","volume":"29","author":"JP Restrepo","year":"2010","unstructured":"Restrepo JP, Molina MP (2010) Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol 29:559\u2013561. doi: 10.1007\/s10067-009-1368-8","journal-title":"Clin Rheumatol"},{"issue":"Suppl 1","key":"124_CR27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-013-0064-z","volume":"28","author":"G Pasut","year":"2014","unstructured":"Pasut G (2014) Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs 28(Suppl 1):15\u201323. doi: 10.1007\/s40259-013-0064-z","journal-title":"BioDrugs"},{"key":"124_CR28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/ICO.0b013e318211400a","volume":"31","author":"PS Tlucek","year":"2012","unstructured":"Tlucek PS, Stone DU (2012) Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. Cornea 31:90\u201391. doi: 10.1097\/ICO.0b013e318211400a","journal-title":"Cornea"},{"key":"124_CR29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jfo.2009.04.029","volume":"32","author":"J Garrec Le","year":"2009","unstructured":"Le Garrec J, Marcelli C, Mouriaux F (2009) Can tumor necrosis factor inhibitors induce sclero-uveitis? J Fr Ophthalmol 32:511","journal-title":"J Fr Ophthalmol"},{"key":"124_CR30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3899\/jrheum.110865","volume":"39","author":"C Gaujoux-Viala","year":"2012","unstructured":"Gaujoux-Viala C, Giampietro C, Gaujoux T, Ea HK, Prati C, Orcel P, Wendling D, Liote F (2012) Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol 39:233\u2013239. doi: 10.3899\/jrheum.110865","journal-title":"J Rheumatol"},{"key":"124_CR31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.autrev.2010.07.006","volume":"9","author":"M Benucci","year":"2010","unstructured":"Benucci M, Manfredi M, Puttini PS, Atzeni F (2010) Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today? Autoimmun Rev 9:801\u2013803. doi: 10.1016\/j.autrev.2010.07.006","journal-title":"Autoimmun Rev"},{"key":"124_CR32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.autrev.2006.02.007","volume":"5","author":"S Vita De","year":"2006","unstructured":"De Vita S, Quartuccio L (2006) Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun Rev 5:443\u2013448. doi: 10.1016\/j.autrev.2006.02.007","journal-title":"Autoimmun Rev"},{"key":"124_CR33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.autrev.2009.08.007","volume":"9","author":"T D\u00f6rner","year":"2009","unstructured":"D\u00f6rner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, Burmester G (2009) Current status on B cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev 9:82\u201389","journal-title":"Autoimmun Rev"},{"key":"124_CR34","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390\u20131400. doi: 10.1002\/art.21778","journal-title":"Arthritis Rheum"},{"key":"124_CR35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","volume":"66","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, Dougados M, Ferraccioli G, Jaeger U, Klareskog L, Kvien TK, Martin-Mola E, Pavelka K (2007) Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 66:143\u2013150","journal-title":"Ann Rheum Dis"},{"key":"124_CR36","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.autrev.2011.04.033","volume":"10","author":"M Visentini","year":"2011","unstructured":"Visentini M, Ludovisi S, Petrarca A, Pulvirenti F, Zaramella M, Monti M, Conti V, Ranieri J, Colantuono S, Fognani E, Piluso A, Tinelli C, Zignego AL, Mondelli MU, Fiorilli M, Casato M (2011) A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 10:714\u2013719. doi: 10.1016\/j.autrev.2011.04.033","journal-title":"Autoimmun Rev"},{"key":"124_CR37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.autrev.2006.02.014","volume":"5","author":"JS Kong","year":"2006","unstructured":"Kong JS, Teuber SS, Gershwin ME (2006) Potential adverse events with biologic response modifiers. Autoimmun Rev 5:471\u2013485. doi: 10.1016\/j.autrev.2006.02.014","journal-title":"Autoimmun Rev"},{"key":"124_CR38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.autrev.2008.11.006","volume":"8","author":"M Garcia-Carrasco","year":"2009","unstructured":"Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, Mendoza-Pinto C, Galarza-Maldonado C, Sandoval-Cruz M, Zamudio-Huerta L, L\u00f3pez-Colombo A, Cervera R (2009) Use of rituximab in systemic lupus erythematosus: an update. Autoimmun Rev 8:343\u2013348","journal-title":"Autoimmun Rev"},{"key":"124_CR39","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.autrev.2010.07.013","volume":"9","author":"F Conti","year":"2010","unstructured":"Conti F, Perricone C, Ceccarelli F, Valesini G (2010) Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: two sides of the same coin. Autoimmun Rev 9:716\u2013720. doi: 10.1016\/j.autrev.2010.07.013","journal-title":"Autoimmun Rev"},{"key":"124_CR40","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/kel098","volume":"45","author":"R Stasi","year":"2006","unstructured":"Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D (2006) Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45:1432\u20131436. doi: 10.1093\/rheumatology\/kel098","journal-title":"Rheumatology (Oxford)"},{"key":"124_CR41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","volume":"257","author":"P Eriksson","year":"2005","unstructured":"Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257:540\u2013548. doi: 10.1111\/j.1365-2796.2005.01494.x","journal-title":"J Intern Med"},{"key":"124_CR42","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.autrev.2009.08.001","volume":"9","author":"GJ Tobon","year":"2010","unstructured":"Tobon GJ, Pers JO, Youinou P, Saraux A (2010) B cell-targeted therapies in Sjogren\u2019s syndrome. Autoimmun Rev 9:224\u2013228. doi: 10.1016\/j.autrev.2009.08.001","journal-title":"Autoimmun Rev"},{"key":"124_CR43","author":"L Quartuccio","year":"2009","unstructured":"Quartuccio L, Fabris M, Salvin S, Maset M, De Marchi G, De Vita S (2009) Controversies on rituximab therapy in Sjogren syndrome-associated lymphoproliferation. Int J Rheumatol. doi: 10.1155\/2009\/424935","journal-title":"Int J Rheumatol"},{"issue":"4","key":"124_CR44","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1442-9071.2006.01225.x","volume":"34","author":"L Lim","year":"2006","unstructured":"Lim L, Suhler EB, Smith JR (2006) Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol 34(4):365\u2013374","journal-title":"Clin Experiment Ophthalmol"},{"key":"124_CR45","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/ard.2004.027128","volume":"64","author":"K Ahmadi-Simab","year":"2005","unstructured":"Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M, Gross WL (2005) Successful treatment of refractory anterior scleritis in primary Sjogren\u2019s syndrome with rituximab. Ann Rheum Dis 64:1087\u20131088. doi: 10.1136\/ard.2004.027128","journal-title":"Ann Rheum Dis"},{"key":"124_CR46","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/bjo.2005.075689","volume":"89","author":"CM Cheung","year":"2005","unstructured":"Cheung CM, Murray PI, Savage CO (2005) Successful treatment of Wegener\u2019s granulomatosis associated scleritis with rituximab. Br J Ophthalmol 89:1542. doi: 10.1136\/bjo.2005.075689","journal-title":"Br J Ophthalmol"},{"key":"124_CR47","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/bjo.2007.133173","volume":"93","author":"PA Kurz","year":"2009","unstructured":"Kurz PA, Suhler EB, Choi D, Rosenbaum JT (2009) Rituximab for treatment of ocular inflammatory disease: a series of four cases. Br J Ophthalmol 93:546\u2013548. doi: 10.1136\/bjo.2007.133173","journal-title":"Br J Ophthalmol"},{"key":"124_CR48","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/bjo.2008.147157","volume":"93","author":"S Chauhan","year":"2009","unstructured":"Chauhan S, Kamal A, Thompson RN, Estrach C, Moots RJ (2009) Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol 93:984\u2013985","journal-title":"Br J Ophthalmol"},{"key":"124_CR49","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/09273940802331643","volume":"16","author":"S Onal","year":"2008","unstructured":"Onal S, Kazokoglu H, Koc A, Yavuz S (2008) Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener\u2019s granulomatosis. Ocul Immunol Inflamm 16:230\u2013232. doi: 10.1080\/09273940802331643","journal-title":"Ocul Immunol Inflamm"},{"key":"124_CR50","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24454","volume":"60","author":"SR Taylor","year":"2009","unstructured":"Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL (2009) Rituximab is effective in the treatment of refractory ophthalmic Wegener\u2019s granulomatosis. Arthritis Rheum 60:1540\u20131547","journal-title":"Arthritis Rheum"},{"key":"124_CR51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/09273941003739928","volume":"18","author":"B Iaccheri","year":"2010","unstructured":"Iaccheri B, Androudi S, Bocci EB, Gerli R, Cagini C, Fiore T (2010) Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm 18:223\u2013225. doi: 10.3109\/09273941003739928","journal-title":"Ocul Immunol Inflamm"},{"key":"124_CR52","first-page":"183","volume":"19","author":"LMZ G\u00f3mez","year":"2012","unstructured":"G\u00f3mez LMZ, Franco CJV, Foronda JCH, Alzate CFC (2012) Uso de rituximabe en una paciente con escleritis anterior difusa necrotizante asociada a vasculitis con c-ANCA refractaria a immunomoduladores convencionales. Rev Colomb Reumatol 19:183\u2013189","journal-title":"Rev Colomb Reumatol"},{"key":"124_CR53","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/09273948.2013.788724","volume":"21","author":"K Bogdanic-Werner","year":"2013","unstructured":"Bogdanic-Werner K, Fernandez-Sanz G, Alejandre Alba N, Ferrer Soldevila P, Romero-Bueno FI, Sanchez-Pernaute O (2013) Rituximab therapy for refractory idiopathic scleritis. Ocul Immunol Inflamm 21:329\u2013332. doi: 10.3109\/09273948.2013","journal-title":"Ocul Immunol Inflamm"},{"key":"124_CR54","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/jamaophthalmol.2013.8179","volume":"132","author":"EB Suhler","year":"2014","unstructured":"Suhler EB, Lim LL, Beardsley RM, Giles TR, Pasadhika S, Lee ST, Sardos AS, Butler NJ, Smith JR, Rosenbaum JT (2014) Rituximab in the treatment of refractory scleritis and non-infeccious orbitary inflammation: preliminary results from a Phase I\/II prospective, randomized, dose-ranging pilot study. JAMA Ophthalmol 132:572\u2013578. doi: 10.1001\/jamaophthalmol.2013.8179","journal-title":"JAMA Ophthalmol"},{"key":"124_CR55","first-page":"S1","volume":"30","author":"G Turchetti","year":"2012","unstructured":"Turchetti G, Smolen JS, Kavanaugh A, Braun J, Pincus T, Bombardieri S (2012) Treat-to-target in rheumatoid arthritis: clinical and pharmacoeconomic considerations. Introduction. Clin Exp Rheumatol 30:S1","journal-title":"Clin Exp Rheumatol"},{"key":"124_CR56","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1442-9071.1991.tb00663.x","volume":"19","author":"P McCluskey","year":"1991","unstructured":"McCluskey P, Wakefield D (1991) Prediction of response to treatment in patients with scleritis using a standardised scoring system. Aust N Z J Ophthalmol 19:211\u2013215","journal-title":"Aust N Z J Ophthalmol"},{"key":"124_CR57","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ophtha.2010.08.027","volume":"118","author":"HN Sen","year":"2011","unstructured":"Sen HN, Sangave AA, Golgstein DA, Suhler EB, Cunningham D, Vitale S, Nussenblatt RB (2011) A stardardized grading system for scleritis. Ophthalmology 118:768\u2013771","journal-title":"Ophthalmology"},{"key":"124_CR58","doi-asserted-by":"crossref","unstructured":"Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ (2005) Updated consensus statement on biological agents, specifically tumor necrosis factor \u03b1 (TNF \u03b1) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 64 Suppl 4:iv2-14. doi: 10.1136\/ard.2005.044941","DOI":"10.1136\/ard.2005.044941"},{"key":"124_CR59","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/bjo.2006.113316","volume":"91","author":"J Freidlin","year":"2007","unstructured":"Freidlin J, Wong IG, Acharya N (2007) Rituximab treatment for peripheral ulcerative keratitis associated with Wegener\u2019s granulomatosis. Br J Ophthalmol 91:1414. doi: 10.1136\/bjo.2006.113316","journal-title":"Br J Ophthalmol"},{"key":"124_CR60","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","volume":"117","author":"CS Foster","year":"2010","unstructured":"Foster CS, Chang PY, Ahmed AR (2010) Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 117:861\u2013869. doi: 10.1016\/j.ophtha.2009.09.049","journal-title":"Ophthalmology"},{"key":"124_CR61","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/ICO.0b013e3181c296ed","volume":"29","author":"V Huerva","year":"2010","unstructured":"Huerva V, Sanchez MC, Traveset A, Jurjo C, Ruiz A (2010) Rituximab for peripheral ulcerative keratitis with Wegener granulomatosis. Cornea 29:708\u2013710. doi: 10.1097\/ICO.0b013e3181c296ed","journal-title":"Cornea"},{"key":"124_CR62","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/14656566.2013.772982","volume":"14","author":"RM Beardsley","year":"2013","unstructured":"Beardsley RM, Suhler EB, Rosenbaum JT, Lin P (2013) Pharmacotherapy of scleritis: current paradigms and future directions. Expert Opin Pharmacother 14:411\u2013424. doi: 10.1517\/14656566.2013.772982","journal-title":"Expert Opin Pharmacother"},{"key":"124_CR63","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00003495-199958010-00009","volume":"58","author":"SV Onrust","year":"1999","unstructured":"Onrust SV, Lamb HM, Balfour JA (1999) Rituximab. Drugs 58:79\u201388","journal-title":"Drugs"},{"issue":"785\u2013796","key":"124_CR64","first-page":"e783","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121(785\u2013796):e783. doi: 10.1016\/j.ophtha.2013.09.048","journal-title":"Ophthalmology"},{"key":"124_CR65","first-page":"734","volume":"126","author":"VPJ Saw","year":"2008","unstructured":"Saw VPJ, Cornelius N, Salama AD, Pusey C, Lightman SL (2008) Infliximab therapy for aggressive Mooren ulceration. Arch Ophthalmol 126:734","journal-title":"Arch Ophthalmol"},{"key":"124_CR66","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12348-012-0080-z","volume":"2","author":"M Cordero-Coma","year":"2012","unstructured":"Cordero-Coma M, M\u00e9ndez RS, Blanco AC, Corral AL, Calleja-Antolin S, Morales JMR (2012) Adalimumab for refractory peripheral ulcerative keratitis. J Ophthal Inflamm Infect 2:227\u2013229. doi: 10.1007\/s12348-012-0080-z","journal-title":"J Ophthal Inflamm Infect"},{"key":"124_CR67","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1442-9071.2007.01609.x","volume":"35","author":"L Fontana","year":"2007","unstructured":"Fontana L, Parente G, Neri P, Reta M, Tassinari G (2007) Favourable response to infliximab in a case of bilateral refractory Mooren\u2019s ulcer. Clin Experiment Ophthalmol. 35:871\u2013873. doi: 10.1111\/j.1442-9071.2007.01609.x","journal-title":"Clin Experiment Ophthalmol."}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-015-0124-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-015-0124-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-015-0124-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:30:37Z","timestamp":1559262637000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-015-0124-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,29]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["124"],"URL":"https:\/\/doi.org\/10.1007\/s10792-015-0124-0","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,29]]}}}